{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:09:26Z","timestamp":1781244566551,"version":"3.54.1"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,12,18]],"date-time":"2011-12-18T00:00:00Z","timestamp":1324166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Short\u2010term studies show that PPIs heal erosive esophagitis in children. There are no prospective studies that examine long\u2010term maintenance therapy of erosive esophagitis in children with and without underlying GERD\u2010predisposing disorders.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To determine prospectively the dose of omeprazole needed to maintain remission of erosive oesophagitis and reflux symptoms in children.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Patients aged 1\u201316\u2003years with healed erosive reflux oesophagitis after omeprazole treatment (0.7\u20133.5\u2003mg\/kg\/day) entered a 21\u2010month maintenance phase where they initially received half the dose of omeprazole required to heal. Endoscopy was performed after 3, 12 and 21\u2003months. The omeprazole dose was increased if erosive oesophagitis or reflux symptoms recurred.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A total of 46 patients entered the study and 32 completed it. Of these, 17 (53%) remained on the maintenance dose, 12 (38%) returned to their healing dose and 3 (9%) ended the study on a dose higher than their healing dose. Three\u2010quarters of the completers (24\/32) had no erosive oesophagitis relapse. Four patients (13%) had relapse of only erosive oesophagitis, 4 (13%) had relapse of erosive oesophagitis and symptoms, and 10 (31%) had only symptomatic relapse. Of the 46 patients, 48% had GERD\u2010predisposing disorders (neurological impairment or oesophageal atresia). Overall, 62.5% (5\/8) of patients who had an erosive oesophagitis relapse had a GERD\u2010predisposing disorder versus 33.3% (8\/24) of those who did not.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Remission of erosive oesophagitis is maintained with omeprazole treatment for at least 21\u2003months in most children aged 1\u201316\u2003years, and the drug is well tolerated. To maintain remission, some 60% of patients require more than half the dose required for healing. In children with GERD\u2010predisposing conditions, GERD is often chronic and relapsing, and requires long\u2010term management.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2011.04950.x","type":"journal-article","created":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T01:52:59Z","timestamp":1324259579000},"page":"368-379","source":"Crossref","is-referenced-by-count":20,"title":["Long\u2010term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study"],"prefix":"10.1111","volume":"35","author":[{"given":"E.","family":"Hassall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Koletzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Radke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lundborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318176b2cb"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81561-6"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.109607"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000214160.37574.d3"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200211004-00003"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.11.034"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/MPG.0b013e3181b7f563","article-title":"Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition","volume":"49","author":"Vandenplas Y","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_6_9_2","first-page":"CD003245","article-title":"Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease","volume":"2","author":"Donnellan C","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01152.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90162-X"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199610000-00001"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000199786"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199305000-00001"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.152.11.1113"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.08.078"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.129"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3182133143"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520510011579"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.145177"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-1655"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.46"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-1543"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.09.054"},{"key":"e_1_2_6_25_2","unstructured":"FDA Communication.Low magnesium levels can be associated with long\u2010term use of proton pump inhibitor drugs (PPIs).2011. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm245011.htm. Accessed December 3 2011."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.44"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.45"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2003.08.015"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.017"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200002000-00020"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200011000-00007"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2007.08.006"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04592.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04950.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2011.04950.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:44:35Z","timestamp":1698738275000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04950.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,18]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1365-2036.2011.04950.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04950.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,18]]}}}